healthy product on the way, page-2

final commercialisation trial plan Imugene proposes to carry out the trials in secure facilities at up to three locations in Victoria. The proposed PC1 animal containment measures include a lockable shed to prevent the escape of the pigs and/or access by other animals. Dissemination of the GM virus would be limited due to its inability to infect organisms other than pigs; by its limited ability to survive in the environment outside its natural host; and the trial sites’ remoteness from other pig rearing facilities or feral pig populations.
During the trial period, from the time of issuing of the licence until December 2006, up to 200 pigs will be inoculated, via intranasal or oral routes or by subcutaneous injection, with one or more of the GM viruses. None of the pigs from the trial, or their by-products, would be used for animal feed or human food. Following each trial, inoculated pigs will be euthanased and all animal material disposed of under strict conditions that would destroy the GMOs.
The aim of the proposed trial is to evaluate the performance of the GM viruses in post-weaning pigs, using a range of indicators such as pig health, weight gain, feed conversion rate and meat quality. The trials will also allow additional research on the potential of the virus to spread from one pig to another within the secure facilities.

Imugene proposes to carry out the trials at up to three locations in Victoria. The proposed PC1 animal containment measures include the use of secure facilities to prevent the escape of the chickens and/or access by other animals. Dissemination of the GM virus would be limited due to its inability to infect organisms other than birds; by its limited ability to survive in the environment outside its natural host; and the trial sites’ remoteness from other chicken production facilities.
During the trial period, from the time of issuing of the licence until December 2006, up to 5000 chickens will be inoculated with the GM viruses. Chickens will be inoculated either in ovo or within the first 2 weeks after hatching (via drinking water, intra-ocular delivery or spray). None of the chickens from the release, or their by-products, would be used for animal feed or human food. Following each trial, inoculated chickens will be euthanased and all animal material disposed of under strict conditions that would destroy the GMOs.
The aim of the proposed trial is to evaluate the performance of the GM viruses in chickens, using a range of indicators such as chicken health, weight gain and feed conversion rate. The trials will also allow additional research on the potential of the viruses to spread from one chicken to another within the secure facilities.